Home » SARC Consortium Members
SARC is an advocate for sarcoma medical research and clinical trials. We facilitate dialogue and collaboration among sarcoma researchers and clinicians, develop and sponsor clinical trials, administer research grants and funding for clinical trials, and act as a primary resource for those treating sarcoma.
SARC is formalizing its current research structure by establishing a consortium of institutional partners via a new, uniform Master Collaboration Agreement. Membership to the SARC Consortium is by invitation only.
The SARC Master Collaboration Agreement (MCA) governs the collaborative relationship and sets forth the primary terms for the conduct of research. The agreement is analogous to other collaborative research agreements to which many of the leading research institutions are already a party, such as agreements with the Alliance for Clinical Trials in Oncology and the National Clinical Trials Network. SARC closely collaborated with a subset of its institutional and academic partners to prepare and arrive at the final MCA. The agreement will streamline collaborations and contracting processes in service of our shared mission to advance research to the benefit of patients globally.
To qualify, institutions must:
As a SARC Consortium Member we encourage your institution’s representatives to:
SARC Consortium Members will be highlighted within the new Sarcoma Centers Registry listing and map. Expected launch Spring 2024.
For more information about membership, contact SARC President & CEO Steven Young.
Sign up for our monthly SARC newsletter and updates on clinical trials.